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1 Introduction
1.1 Peripheral Neuropathies
Peripheral neuropathies represent one of the most commonly found symptoms in neurological
patients. They are due to various causes including complex medical conditions (e.g. diabetes
mellitus), toxic metabolites (e.g. thallium, arsenic), drugs (e.g. fluoroquinolone, vincristine,
isoniazid,  cisplatin),  infections  (e.g.  borrelia  burgdorferi,  mycobacterium  leprae)  and
hereditary  causes  (e.g.  Friedreich’s  ataxia,  Charcot-Marie-Tooth  disease).  Mycobacterium
leprae  and malnutrition  are  the  most  commonly  found causes  for  peripheral  neuropathies
today in  developing  countries,  while  alcohol  abuse  and diabetes  mellitus  are  the  leading
causes for these symptoms in industrialized parts of the world (Masuhr and Neumann, 2007;
Weiss et al., 2012). 
Since many forms of neuropathies are acquired, inherited peripheral neuropathies represent a
minority among all forms of neuropathies. The first causative gene loci have been discovered
within  the  last  two  decades.  So  far,  about  50  loci and  30  causative  genes have  been
successfully  identified  and  linked  to  the  group  of  inherited  peripheral  neuropathies.  An
updated  list  on  molecular  genetic  studies  and  recently  identified  genes  and  loci can  be
retrieved  on:  http://www.molgen.ua.ac.be/CMTMutations/Home/IPN.cfm (information
retrieved on 17th October 2012). 
Recently, clinicians started to distinguish inherited neuropathies based on their origin, as they
classify them in neuropathies, (I) in which the neuropathy is the main symptom of the disease
(e.g.  Charcot-Marie-Tooth disease (CMT), hereditary neuropathy with liability to pressure
palsies (HNPP)) and neuropathies, (II) in which the clinical manifestation is part of a more
widespread  neurological  or  multisystem  disorder  (e.g.  Leukodystrophies,  Porphyrias,
Friedreich’s ataxia) (Reilly, 2007). 
1.2 Charcot-Marie-Tooth disease
The  Charcot-Marie-Tooth  (CMT)  disease,  also  known  as  hereditary  motor  and  sensory
neuropathy (HMSN), was first described by J.-M. Charcot, P. Marie and H. H. Tooth in 1886
(Irobi et al., 2004). The Charcot-Marie-Tooth disease affects approximately 1 in 2,500 people
(Skre, 1974). More recent investigations indicate an unsuspected higher prevalence of 1 in
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1,214  people  in  Western  Europe  (Braathen,  2012).  There  are  estimations  about  30,000
affected  patients  suffering  from  Charcot-Marie-Tooth  disease  in  Germany  (Grehl  and
Rautenstrauß, 1997). Thus, CMT is considered a rare neurological disease (Murphy et al.,
2012). The number of un- and misdiagnosed patients remains unknown. Possible differential
diagnoses include e.g. poliomyelitis, Friedreich ataxia, hereditary neuropathy with liability to
pressure palsies (HNPP), Déjerine-Sottas disease (DSD), congenital hypomyelination (CH),
Refsum’s disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and
spinal muscular atrophy (Pareyson, 2004; Hanemann and Ludolph, 2002). 
CMT is a synonym for a heterogeneous group of inherited neuropathies (Lupski and Garcia,
1992).  It  can  be  distinguished  in  autosomal  dominant  demyelination  (CMT1),  axonal
(CMT2), X-linked (CMT1X) and autosomal-recessive types of neuropathies (Patzkó and Shy,
2012). Taking into consideration the nerve conduction velocity (NCV), there can be made a
clinical assessment and a fairly solid prediction of the type of inheritance. Since NCVs with
less than 38 m/s are characteristic of CMT type 1 and NCVs above 38 m/s are typical of
axonal  CMT2.  Intermediate  NCVs  (25-45  m/s)  are  often  associated  with  male  patients
suffering from CMT1X (Patzkó and Shy, 2011; Reilly and Shy, 2009). 
Around two third of CMT patients suffer from type 1A, which is therefore the most common
subtype  (Pareyson,  2004).  CMT1A has  an autosomal-dominant  inheritance  pattern  and is
caused  by  an  intrachromosomal  duplication  of  the  gene  pmp22  located  on  chromosome
17p11.2  (Vance  et  al.,  1989;  Raeymaekers  et  al.,  1991,  Lupski  and  Garcia,  1992).  The
encoded protein PMP22 is a small tetraspanned 22-kDa membrane glycoprotein, which plays
a crucial role in myelin assembly and synthesis. 
Subtle  changes  in  gene-dosages  are  remarkable,  as  they  are  responsible  for  a  range  of
neuropathy  related  diseases.  While  e.g.  the  duplication  is  shown  to  be  responsible  for
CMT1A,  a  haplo-insufficiency  by deletion  is  associated  with  hereditary  neuropathy  with
liability to pressure palsies (HNPP), emphasizing the importance of correct dosage of PMP22.
The modulation of the PMP22 dosage is now even considered to be a promising therapeutic
approach in CMT1A (Jang et al., 2012). 
HNPP in contrast to CMT, can be entirely asymptomatic until triggered and then present with
episodes  of  recurrent  painless  focal  motor  and  sensory  peripheral  mono-neuropathies.
Characteristically, symptoms are limited to areas of so called 'entrapment' like wrists, elbows,
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knees and shoulders.  Thus, alterations in the same  gene loci of chromosome 17p11.2 can
result in utterly different clinical phenotypes (Rana and Masroor, 2012).
1.2.1 Charcot-Marie-Tooth disease type 1A
CMT1A is a non-lethal, slowly progressive neuromuscular disorder. Age of onset is usually
within the first two decades of life (Reilly et al., 2011). Patients suffer from a wide range of
symptoms with varying degrees of severity. 
Characteristic for CMT1A is distally pronounced muscle wasting and consecutive weakness.
Furthermore,  typical  symptoms  include  steppage  gait,  impaired  fine  motor  skills,  distal
sensory  impairment,  hyporeflexion  (in  particular  altered  tendon  reflexes)  and  skeletal
deformities  (pes  cavus  formation  [Figure  1])   (Pareyson,  2004;  d'Ydewalle  et  al.,  2012;
Patzkó and Shy, 2011). Apart from peripheral demyelination and consecutive axonal loss, so
called onion bulb formations [Figure 2] in peripheral nerve biopsies are distinctive findings
in CMT1A (Reilly, 2007). 
Furthermore, it was recently shown that approximately 16 % of patients with CMT1A suffer
from clinical depression due to slowly progressive loss of physical  abilities and uncertain
predictions  regarding  their  respective  future  quality  of  life  (e.g.  being  wheelchair-bound)
(Ribiere et al., 2012).   
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1.2.2
Charcot-Marie-Tooth Neuropathy Score (CMTNS)
The most common clinical score to classify the severity of patients suffering from CMT1A is
so far the  Charcot-Marie-Tooth Neuropathy Score (CMTNS)  [Table 1] (Shy et al., 2005).
This scoring system consists of nine parameters, which are evaluated on a scale from 0 to 4.
The single parameter subscores are added. Thus, the maximum CMTNS-value can amount to
36  points.  The  disease  severity  positively  correlates  with  the  number  of  CMTNS points
achieved during a clinical examination performed by a physician. The CMTNS (Version 1) is
derived  from the  Total  Neuropathy  Score  (TNS)  (Cornblath  et  al.,  1999)  [Table  3]  and
adapted  to  the special  symptoms of  CMT patients.  The ratio  between motor  and sensory
symptoms in the CMTNS is unbalanced in favour of motor symptoms. There are five motor
and just four sensory parameters included in this clinical scoring system (Shy et al., 2005). 
Recently the CMTNS was published in its second and revised version (CMTNS2) (Murphy et
al., 2011) [Table 2]. In this revised version spoken instructions are provided. The scaling of
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Figure  1: Pes cavus foot deformation in patients included in the prospective
clinical trial.
Depicted are elevated longitudinal plantar archs as the characteristic feature
of pes cavus foot deformation (Karakis et al., 2013). Further visible is distally
pronounced  muscle  wasting.  Picture  A shows  the  complete  inability  of  the
patient  to  perform  a  dorsal  flexion  due  to  advanced  atrophy  of  peroneus
muscles. On this account the patient in A and B suffers from steppage gait.
[Photos by M. Mannil]
Figure 2: onion bulb formation in sural nerve biopsy; [Reilly, 2007, p. 98]
(A) thinly myelinated and (B) completely demyelinated axons as characteristic findings
in sural  nerve biopsies  in  a patient  suffering from CMT1.  The onion bulb formation
consists of  multiple dysfunctional Schwann cell processes (arrows) (Reilly, 2007).
  1 Introduction
the parameters was slightly changed and the often absent Sensory Nerve Action Potential
(Ulnar SNAP) parameter was omitted and replaced with Radial Sensory Action Potentials
(Radial SAP). Nevertheless, the CMTNS (Version 1) is still the most commonly used scoring
system in clinical settings and trials (Pareyson et al., 2011). 
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Table 1: Charcot-Marie-Tooth Neuropathy Score (Version 1) [Shy et al., 2005, p. 1210]
The Charcot-Marie-Tooth Neuropathy Score (Version 1) is used to assess the clinical disease
severity of CMT patients of all common subtypes. The achieved subscores are added to a total
score, which positively correlates with the individual disease affection. Thus, the minimum
score is 0 points and the maximum score amounts to 36 points. 
Score  values  of  10  and below,  indicate  mild  affection.  Score  values  between  11 and 20
indicate moderate affection and score values above 20 indicate a severe clinical phenotype
(Shy et al., 2005). 
  1 Introduction
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Table 2: CMTNS2 (Version 2) (second and revised version) [Murphy et al., 2011, p. 193]
In the revised version of the CMTNS (Version 2) the parameter Ulnar SNAP was omitted and
replaced with Radial SAP. Other parameters e.g. ankle surgery, usage of buttons and AFO
were altered. Furthermore, detailed spoken instructions (in English language) are provided.
  1 Introduction
Parameter
Score
0 1 2 3 4
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Table 3: Total Neuropathy Score (TNS) [modified from Cornblath et al., 1999]
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The  sensory  symptoms  in  the  CMTNS  (Shy  et  al.,  2005)  include  the  affected  area  of
impairment (limited to toes, ankle, knee or above). Furthermore, it includes the pin sensibility,
which is examined by using a sharp edged device and a cotton bud on different areas of a
blind-folded  patient.  Another  method  being  used  in  the  CMTNS  to  determine  sensory
symptoms  is  using  a  Reidel-Seiffer-Tuning-Fork  to  determine  pallesthesia.   Sensory
symptoms  also  include  sensory  neurological  action  potentials  (SNAP)  measured  using
electroneurography on ulnar  or alternatively median  nerves.  Due to the high incidence  of
carpal  tunnel  syndromes  in  the  general  population,  measurements  on  the  ulnar  nerve  are
preferred. Motor symptoms are assessed by taking the patient's history (usage of walking aids,
fine  motor  skills),  by measuring  the  strength  of  arms  and legs  according  to  the  Medical
Research Council (MRC) Scale for muscle strength and by measuring the compound muscle
action potential (CMAP) by electroneurography on ulnar (preferred) or median nerves. 
The overall Charcot-Marie-Tooth Neuropathy Score reliably states the grade of affection. A
CMTNS < or = 10 shows mild, a CMTNS from 11 to 20 shows moderate and a score equaling
21 or above indicates severe affection (Shy et al., 2005).  
1.3 Secondary clinical outcome measures
Secondary clinical outcome measures represent alternative examination techniques in order to
improve the assessment of disease severity in CMT patients. These examinations include the
Overall Neuropathy Limitations Scale (ONLS), 9-hole-peg test, 10m-timed walking as well as
extensive dynamometry tests. These items were proven to provide sufficient intra- and inter-
rater reliability and represent promising additions to future score generations (Solari et al.,
2008).  
The Overall  Neuropathy Limitation Scale (ONLS) includes the patients  ability to perform
everyday tasks and grades the impairment of lower and upper extremities summarized in a
short form (Graham and Hughes, 2006). The 9-hole-peg test is used to evaluate the fine motor
skills  in patients  suffering from various diseases.  The patients need to place nine pegs in
preformed holes and retrieve them afterwards. The examination is performed with both the
dominant and non-dominant hand and is timed (Earhart et al., 2011). The 10m-timed walking
is  performed  barefoot  on  even  ground.  For  the  dynamometry  tests,  a  CITEC©-handheld
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dynamometry device was used, performing different subsets of tests, for instance the three-
point grip, pinch-grip, fist-grip, foot dorsal and doot plantar measurements (Solari et al., 2008;
Spink et al., 2010). 
1.4 Aims and perspective
The aim of this prospective, multi-centre clinical trial is to identify new secondary clinical
outcome measures and validate them in a subset of CMT1A patients. At a later stage, this
very information will be used to clinically validate biomarkers in skin biopsies and whole
blood.
New outome measures are needed, since the current scoring systems like the CMTNS are
reliable and valid to distinguish between mildly and severely affected patients, but reach their
limitations  especially with regard to change over time.  The CMTNS changes merely 0.2-
0.686 points/ year and there are indications that the progression rate increases with age  (Shy
et  al.,  2008;  Pareyson  et  al.,  2011).  In  a  slowly  progressive  neuropathy  like  CMT1A,
biomarkers as well as valid and reliable clinical outcome measures are desirable, in order to
see a significant effect of therapeutic trials within a reasonable amount of time. 
The main goal regarding the clinical outcome measurements is to first establish secondary
clinical outcome measures in CMT1A as putative additions to the current scoring systems and
to validate the currently frequently used CMTNS. In a second step all patients from Germany
will be re-examined after 2.5 to 3 years, in order to investigate the aspect of change over time.
   - 9 -                                                                 
  2 Material and methods
2 Material and methods
2.1 Material for patient examination
sterile surgical gloves Paul Hartmann AG, Heidenheim 
syringe 1 ml Becton Dickinson GmbH,  Heidelberg 
disposables needles Becton Dickinson GmbH,  Heidelberg 
underlayment sheet, Moli Nea plus L Paul Hartmann AG, Heidenheim 
desinfection spray, Kodan Tinktur forte Schülke & Mayr GmbH, Norderstedt 
disposable tweezers Department of Neurosurgery, UMG 
Biopsy Punch, 3mm diameter Stiefel GmbH, Wächtersbach 
sterile cotton balls Paul Hartmann AG, Heidenheim 
sterile Falcon Becton Dickinson GmbH, Heidelberg 
scalpel, Techno cut HDM Healthcare, Hereford, UK 
Steri Strip 3M Health Care, St. Paul, USA 
Durapore patches 3M Health Care, St. Paul, USA 
CryoPure container, 1.6 ml (red, yellow) Sarstedt AG & Co, Nümbrecht 
Q-Tips Karl Beese Verbandstoffe, Barsbüttel 
Table 4: Disposable items
Xylocain, 1 % AstraZeneca GmbH, Wedel
4 % PFA MPI Experimental Medicine
RNAlater©  AMBION Inc., Austin, USA
Table 5: Chemicals
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9 peg hole test Sammons Preston, Illinois, USA 
CITEC©  Dynamometry CIT Technics, Haren, NL 
electronic time clock Aristo, USA
Table 6: Devices
Office Word 2010 Microsoft, Seattle, USA 
Office Excel 2010 Microsoft, Seattle, USA 
Libre Office 3.4.4 Document Foundation, Open Source
MiKTeX, LaTeX C/o Christian Schenk, OpenSource
Statistica 9 StatSoft, Hamburg
Statistical Software Package R version 2.15.0 The  R  Project  For  Statistical  Computing,
OpenSource
Adobe Illustrator CS5 Adobe Systems, San Jose, USA
Table 7: Software
2.2 Material for RNA purification from human whole blood
QIAamp® RNA Blood Mini Kit Qiagen, Hilden
pipets and sterile, RNase-free pipet tips Qiagen, Hilden
microcentrifuge with rotor for 2 ml tubes EuroClone, Mini Speedy, Milano, Italy
ethanol (96-100 %) MPI Experimental Medicine
70 % ethanol in water MPI Experimental Medicine
14.3 M β-mercaptoethanol (β-ME) Qiagen, Hilden
sterile, disposable, polypropylene tubes (1.5-
15 ml depending on sample size)
Qiagen, Hilden
Table 8: RNA purification material
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2.3 Protocol for RNA purification from human whole blood1 
1. Material: 1.5 ml whole blood in EDTA-K tube (cooled on ice for maximum 4 h, if not
purified immediately)
2. Mix 1.5 ml of human whole blood with 7.5 ml of buffer EL 
3. Incubate for 10-15 min on ice. Vortex shortly twice during incubation.
4. Centrifuge at 400 g for 10 min at 4°C and completely remove and discard supernatant.
5. Add Buffer EL to the cell  pellet  (twice the amount  of Buffer EL compared to the
amount of whole blood). Vortex briefly.
6. Centrifuge at 400 g for 10 min at 4°C and completely remove and discard supernatant.
7. Add Buffer RLT to pelleted leukocytes according to the table below. Vortex or pipet
to mix:
Buffer RLT (µl) whole blood (ml) No. of leukocytes
350 Up to 0.5 Up to 2 x 106
600 0.5 to 1.5 2 x106 to 1 x 107
Table 9: Amount of Buffer RLT  [Riemann et al., 2007]1
2.4 Patient collective
The study 'Validation of prognostic and diagnostic markers in Charcot-Marie-Tooth disease
type 1A (HMSN1A)' was initiated in Göttingen in 2009. The patients were examined within
Germany in Munich and Göttingen. Apart from that, CMT1A patients from Italy, Spain and
Czech Republic were also included for the finding of secondary outcome measures and the
establishment of biomarkers. Additionally, baseline data of the ascorbic acid trial in Italy and
the United Kingdom were used as well (Pareyson et al., 2011). A total of 479 patients with
genetic  proof  of  CMT1A  by  duplication  of  pmp22  on  chromosome  17p11.2  have  been
examined. The inclusion and exclusion criteria to participate in the multi-centre, prospective
study are mentioned below [Table 10].   In near future further patients will also be recruited
in France, United Kingdom, Belgium and Münster/ Germany. The eligibility criteria as well
as the exact examination protocols remain unchanged.  
1 modified from RNA Blood mini kit, Qiagen, Hilden
 - 12 -                                                                     
  2 Material and methods
Inclusion criteria Exclusion criteria
informed consent other neurological disease (acute or prior)
genetical evidence of CMT1A age <18 and >70 years
clinical manifestation of CMT1A (pre-) existence of any prior severe internal or
psychiatric diseases
no fulfilment of any exclusion criteria drug, substance or alcohol dependencies
receptive or global aphasia
participation in other clinical trials within the
last 8 weeks
Table 10: Inclusion and exclusion criteria for participation
2.4.1 Patient recruitment
Since CMT1A is considered to be a rare neurological disease (Murphy et al., 2012) and due to
strict study in- and exclusion criteria, the patient recruitment proved to be cumbersome. In
order  to still  recruit  a  cohort  of 479 patients  various  sources  were used.  In  Germany for
instance, patient initiatives (e.g.  Deutsche Gesellschaft für Muskelkranke e.V.) and referrals
from  other  medical  institutions  (University  Clinic  Münster,  Rehabilitation  Clinic  Hoher
Meissner, Klinikum Kassel, etc.) were one source of putative study participants. 
The  recruitment  was  extended  to  announcements  in  specific  internet  forums
(http://www.dgm.org/dgm-forum/; http://www.hmsn.de; http://www.intakt.info/forum/) and on
the  webpage  of  the  Max-Planck-Institute  For  Experimental  Medicine  [Figure  3] and  the
Universitätsmedizin  Göttingen  (UMG)  (http://www.em.mpg.de/index.php?id=279;
http://www.neurologie.uni-goettingen.de/index.php/cmt1a-studie.html)  [information  retrieved
on 10th December 2012]. 
Apart  from  patient-focused  advertisement,  selected  medical  professionals  in  the  field  of
rehabilitation  medicine,  neurology  and  orthopedic  surgery  were  informed  about  the
prospective clinical trial,  in order to raise awareness among physicians and to increase the
number of referrals. Due to the autosomal dominant inheritance pattern of CMT1A, relatives
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of already recruited patients were an additional source of study participants, while doctor-
patient  confidentiality  was  remained  at  all  times.  Furthermore,  the  patient  data  were
pseudonymised,  indicating  only  the  country  of  examination  for  the  purpose  of  detecting
cohort-specific batch effects.  
Further information on the patient collective is described in section 3.1.
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Figure 3. Webpage of CMT1A Trial in Göttingen
information retrieved on 23rd July 2013 under http://www.em.mpg.de/index.php?id=279 
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2.5 SOP – Standard Operation Procedure
1. Provide sufficient information material about the study >72h before the date of the
examination.  Obtain  informed  consent  at  the  day  of  the  examination;  answer  all
arousing questions.
2. Take a complete and thorough history of the patient with special focus on age of onset,
associated symptoms/  diseases, side medications,  inheritance (draw pedigree),  prior
surgeries and usage of walking aids (AFO etc.).
3. Handheld-dynamometry,  CITEC©:  start  with  non-dominant  hand;  fist  grip  (patient
presses device by closing his/  her fist);  three point grip (patient uses Dig. I,II,III);
pinch grip (patient uses Dig. I,II); foot plantar flexion; foot dorsal extension2; verbal
encouragement is mandatory;
4. 9-peg-hole-test: start with non-dominant hand; patient has to fill in all 9 holes with the
provided pins and remove them again afterwards; make sure patients do not use more
than one pin at a time; measure the time from start of examination till the last pin is
being removed; repeat three times per side;
5. Conduct complete neurological physical examination (including reflexes, pallesthesia,
etc.)
6. Patient has to fill in the SF-36 questionnaire and mark a visual analogue scale (10cm)
corncerning current subjective pain perception) 
7. Take  blood  for  general  parameters  (including  VitB12,  TSH,  fT3,  fT4,  infectious
parameters and HbA1c); Take additional 3ml EDTA Blood and immediately cool on
ice;  perform  RNA  purification  within  3  hours  after  drawing  blood,  utilizing  the
Quiagen™-QIAmp-RNA-Blood-Mini-Kit; Store in Eppendorf-tube™ at -80°C;
8. Perform electrophysiological  examination;  preferably  with  SNAP/  CMAP (base  to
peak) from Ulnaris nerve, due to high incidence of carpal tunnel syndrome;
9. Perform skin biopsy from medial index finger of the non-dominant hand (diameter
3mm);  proceed in a sterile  manner  (use sterile  biopsy punches,  scalpels,  tweezers,
cotton wool, etc.); disinfect finger and surrounding area with disinfectant spray; wipe
finger with a sterile cloth once; repeat disinfection three times; give local anaesthesia
2 Usage of a leg fixation device in foot plantar flexion and foot dorsal extension is highly recommended  (Solari
et al., 2008)
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(0.5-2ml lidocaine);  wait  for several minutes,  till  the finger becomes numb; repeat
disinfection procedure; wear surgical gloves; turn biopsy into the finger without using
force; lift the biopsy with sterile tweezers; cut it from below with a disposable scalpel;
divide biopsy and put 1st half in RNAlater™ (store for 24 hours in 4°C and afterwards
in -20°C); put 2nd half in 4% PFA (max. 1 week old); Close the 3mm wound with 3M-
Steri-Strips™, sterile cotton wool and a white plaster;
10. Send a physician report about the findings of the general blood results and the physical
examination to the patient’s general practitioner; 
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3  Results
3.1 Descriptive analysis
The  BMBF-  and  AFM-  funded  clinical  prospective  study  ‚Validation  of  prognostic  and
diagnostic  markers  in  Charcot-Marie-Tooth  disease  type  1A (HMSN1A)‘  was  initiated  in
2009  in  Göttingen  and  aims  at  generating  biomarkers  in  skin  and  whole  blood  and
furthermore  at  validating  secondary  clinical  outcome  measures  (e.g.  CITEC© handheld
dynamometry examinations, 10m-timed walking, 9-peg-hole tests, etc.) as putative additions
to current scoring systems. 
This thesis emphasizes on the analysis of secondary clinical outcome measures in CMT1A: 
479  patients  with  diagnosed  Charcot-Marie-Tooth  disease  type  1A were  included  in  this
clinical  prospective  trial.  These  479  patients  were  recruited  for  the  biomarker  trial  in  5
different centers, namely Italy (it), Spain (spa), Czech Republic (cz), Munich (mue) as well as
Göttingen (goe) and in context of the baseline assessments of the ascorbic acid trial in Italy
and the United Kingdom (Pareyson et al., 2011).  Overall there are 58 % female and 42 %
male patients, while the median age of examination is 42 years. The median Charcot-Marie-
Tooth Neuropathy Score (CMTNS) - as depicted in [Table 11] - is 13. The Body Mass Index
(BMI) is 25 kg/m² and the vast majority of patients neither suffer from any side diagnoses,
nor do they smoke (89 %) or frequently drink alcohol (99 %). The different cohorts represent
well the averagely affected patients suffering from CMT1A in Western Europe. 
The first 21 patients were already re-examined exactly 3 years after the initial examination
and the preliminary results of 10 patients are shown [Table 12]. Apart from the analysis of
validity and reliability of secondary clinical outcome measures, the item ‚change over time‘ is
of particular  interest  in  score generation as well  as in investigation  of biomarkers.   Even
though the final analysis with respect to ‚change over time‘ will be performed as soon as
previous  participants  from  Munich  will  be  re-examined,  preliminary  findings  suggest  an
increase in the CMTNS and therefore an aggravated clinical phenotype with time. 
For better comparison a cohort of 26 healthy controls was recruited additionally for the study
[Table 13] and reference values of the CITEC© handheld dynamometry were used.  
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Parameter Statistics Median (min.; max.) NAs
gender   0
| m 202 (42%)   
| w 277 (58%)   
date of Birth 1966-02-12 1965-09-30 (1936-02-
20; 1993-12-03)
1
age at examination 
[years]
42 ± 13 43 (18; 71) 0
genetic proof   0
| no 7 (1%)   
| yes 472 (99%)   
family history   275
| neg 21 (10%)   
| pos 183 (90%)   
imprinting   328
| maternal 67 (44%)   
| paternal 77 (51%)   
| sporadic 7 (5%)   
weight [kg] 70 ± 15 68 (1; 160) 3
height [cm] 168 ± 9.1 168 (147; 193) 13
CMTNS [0/…/36] 14 13 (3; 32) 4
CMAP (medianus) 
[mV]
2.9 ± 2.5 2.5 (0; 16) 286
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Parameter Statistics Median (min.; max.) NAs
SNAP (medianus) 
[μV]
1.8 ± 4.5 0 (0; 55) 43
10m walk test [sec] 8.4 ± 4.5 7.3 (2.8; 40) 7
9 peg hole test 
(dominant hand) [sec]
24 ± 11 22 (8.8; 165) 5
9 peg hole test (non-
dominant hand) [sec]
26 ± 10 23 (15; 141) 8
visual analogue scale 
[mm]
32 ± 30 23 (0; 100) 4
fist grip (dominant 
hand) [kg]
172 ± 85 156 (0; 476) 4
three point grip 
(dominant hand) [kg]
122 ± 59 116 (6; 320) 6
pinch grip (dominant 
hand) [kg]
58 ± 37 49 (5.2; 276) 277
foot dorsal (dominant 
foot) [kg]
119 ± 100 100 (0; 892) 12
foot plantar (dominant 
foot) [kg]
183 ± 122 160 (0; 910) 9
fist grip (non-dominant
hand) [kg]
162 ± 84 141 (12; 486) 276
three point grip (non-
dominant hand) [kg]
105 ± 53 100 (8.7; 302) 277
pinch grip (non-
dominant hand) [kg]
56 ± 34 48 (0; 236) 277
foot dorsal (non-
dominant foot) [kg]
101 ± 86 73 (0; 319) 280
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Parameter Statistics Median (min.; max.) NAs
foot plantar (non-
dominant foot) [kg]
160 ± 109 133 (0; 437) 278
sensory symptoms 
[0/1/2/3/4]
1.1 1 (0; 4) 4
motor symptoms legs 
[0/1/2/3/4]
1.2 1 (0; 4) 4
motor symptoms arms 
[0/1/2/3/4]
0.65 1 (0; 4) 4
pin sensibility 
[0/1/2/3/4]
1.5 2 (0; 4) 4
vibration [0/1/2/3/4] 2 2 (0; 4) 4
strength of legs 
[0/1/2/3/4]
1.5 1 (0; 4) 4
strength of arms 
[0/1/2/3/4]
0.96 1 (0; 4) 4
Ulnar CMAP (Median)
[0/1/2/3/4]
1.8 2 (0; 4) 8
Ulnar SNAP (Median) 
[0/1/2/3/4]
3.4 4 (0; 4) 8
cohort   0
| cz 27 (6%)   
| goe_1 21 (4%)   
| goe_2 45 (9%)   
| it+uk 271 (57%)   
| mue_1 25 (5%)   
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Parameter Statistics Median (min.; max.) NAs
| mue_2 40 (8%)   
| spa 50 (10%)   
age of onset [years] 10 ± 10 6 (0; 40) 417
contraceptive   412
| yes 5 (7%)   
| no 62 (93%)   
problems in pregnancy   408
| yes 4 (6%)   
| no 67 (94%)   
nicotine   409
| no 56 (80%)   
| yes 10 (14%)   
| past 4 (6%)   
packyears 11 ± 15 0 (0; 42) 452
alcohol frequency   408
| no 51 (72%)   
| past 1 (1%)   
| yes_infrequent 19 (27%)   
| yes_often 0 (0%)   
alcohol amount [g/d] 10 ± 19 0 (0; 80) 415
thyroid   429
 - 21 -
  3 Results
Parameter Statistics Median (min.; max.) NAs
| no 44 (88%)   
| yes 6 (12%)   
| past 0 (0%)   
family 7.8 ± 3.7 9 (1; 15) 430
orthopedic shoes   429
| cane 1 (2%)   
| crutches 1 (2%)   
|crutches, hip operation 1 (2%)   
| no 46 (92%)   
| orthopedic shoes 1 (2%)   
CMAP (Ulnaris) [mV] 2.2 ± 1.6 2 (0.1; 5.5) 455
SNAP (Ulnaris) [μV] 2.6 ± 3.5 0.5 (0; 10) 463
BMI [kg/(m2)] 25 ± 4.4 25 (11; 49) 16
Table 11: Descriptive statistics
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Parameter Statistics Median (min.; max.) NAs
gender   0
| m 6 (60%)   
| w 4 (40%)   
date of birth 1965-01-30 1962-09-04 (1953-07-
03; 1985-02-09)
0
age at examination 
[years]
48 ± 9 50 (27; 58) 0
genetic proof   0
| no 0 (0%)   
| yes 10 (100%)   
family history   0
| neg 1 (10%)   
| pos 9 (90%)   
imprinting   2
| maternal 2 (25%)   
| paternal 6 (75%)   
| sporadic 0 (0%)   
weight [kg] 78 ± 12 83 (56; 96) 0
height [cm] 174 ± 9.9 176 (154; 185) 0
CMTNS [0/…/36] 18 18 (14; 22) 0
CMAP (medianus) 
[mV]
1.2 ± 0.78 1.3 (0.3; 2.6) 0
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Parameter Statistics Median (min.; max.) NAs
SNAP (medianus) 
[μV]
6.7 ± 6 8.9 (0; 14) 0
10m walk test [sec] 12 ± 4.6 11 (6.3; 21) 0
9 peg hole test 
(dominant hand) [sec]
28 ± 7.5 28 (21; 40) 0
9 peg hole test (non-
dominant hand) [sec]
30 ± 11 28 (19; 51) 0
visual analogue scale 
[mm]
38 ± 35 30 (0; 99) 0
fist grip (dominant 
hand) [kg]
145 ± 65 131 (74; 291) 0
three point grip 
(dominant hand) [kg]
88 ± 53 82 (25; 215) 0
pinch grip (dominant 
hand) [kg]
55 ± 21 54 (31; 103) 0
foot dorsal (dominant 
foot) [kg]
37 ± 25 35 (0; 76) 1
foot plantar (dominant 
foot) [kg]
89 ± 28 99 (41; 122) 1
fist grip (non-dominant
hand) [kg]
137 ± 58 116 (73; 265) 0
three point grip (non-
dominant hand) [kg]
98 ± 52 93 (17; 217) 0
pinch grip (non-
dominant hand) [kg]
51 ± 21 47 (22; 91) 0
foot dorsal (non-
dominant foot) [kg]
42 ± 24 40 (0; 80) 1
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Parameter Statistics Median (min.; max.) NAs
foot plantar (non-
dominant foot) [kg]
86 ± 32 82 (45; 144) 1
sensory symptoms 
[0/1/2/3/4]
2.5 2 (2; 4) 0
motor symptoms legs 
[0/1/2/3/4]
1.6 1.5 (1; 3) 0
motor symptoms arms 
[0/1/2/3/4]
1.4 1 (1; 3) 0
pin sensibility 
[0/1/2/3/4]
2.1 2 (0; 3) 0
vibration [0/1/2/3/4] 2.8 3 (2; 4) 0
strength of legs 
[0/1/2/3/4]
1.5 1 (1; 3) 0
strength of arms 
[0/1/2/3/4]
0.8 1 (0; 2) 0
Ulnar CMAP (Median)
[0/1/2/3/4]
2.4 2 (2; 3) 0
Ulnar SNAP (Median) 
[0/1/2/3/4]
2.7 2 (1; 4) 0
BMI [kg/(m2)] 26 ± 3.2 26 (19; 30) 0
Table 12: Follow up subgroup; 
Descriptive values of the measured parameters on the follow-up evaluation of the treatment
group. The second column contains mean ± sd where appropriate. For scores, the standard
deviation  was  omitted.  For  categorical  variables  the  fraction  of  the  different  levels  in
absolute values as well as percentages are shown instead.
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Parameter Statistics Median (min.; max.) NAs
gender   0
| m 14 (54%)   
| w 12 (46%)   
date of birth 1983-08-07 1984-01-06 (1963-07-
06; 2011-06-02)
0
age at examination 
[years]
28 ± 7.4 27 (20; 47) 0
weight [kg] 72 ± 13 73 (49; 95) 0
height [cm] 177 ± 10 178 (156; 204) 0
10m walk test [sec] 4.7 ± 0.53 4.7 (3.4; 5.6) 1
9 peg hole test 
(dominant hand) [sec]
16 ± 1.8 16 (14; 20) 1
9 peg hole test (non-
dominant hand) [sec]
17 ± 2.1 17 (14; 22) 1
date of inclusion 2011-05-12 2011-05-05 (2011-02-
18; 2011-10-11)
0
BMI [kg/(m2)] 23 ± 2.8 23 (17; 29) 0
Table 13: Healthy controls; 
Descriptive values of the measured parameters on the control group; The second column
contains mean ± sd where appropriate. For scores, the standard deviation was omitted. For
categorical  variables  the  fraction  of  the  different  levels  in  absolute  values  as  well  as
percentages are shown instead.
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The remarkable amount of participants (n= 479) enabled the investigation of other aspects of
the  Charcot-Marie-Tooth  disease  type  1A as  well.  While  CMT1A is  well  known for  its
autosomal dominant inheritance pattern, statements according to imprinting for instance vary.
In our analysis, the CMTNS in maternally-inherited CMT1A patients is in tendency lower
than in paternally-inherited ones  [Table 14], but the effect is not significant (according to
p≤0,05). In this model, only age shows a significant impact on the CMTNS as an outcome
measure for increasing disease severity. 
For  the  analysis  of  anticipation,  the  data  set  is  not  sufficient  yet,  since  individual  study
participants  outnumber  related  ones  of  different  generations.  However,  literature  review
indicates the existence of anticipation, which will be a matter of interest  in future cohorts
(Kovach et al., 2002; Steiner et al., 2008).
Other findings included complications during pregnancy, which 4 out of 71 females (6 %)
stated  and  hypothyroidism,  which  12  %  of  the  mainly  German  cohort  suffers  from.
Nevertheless, severe side effects cannot be seen, since they represent exclusion criteria in the
clinical study setting. 
 Estimate Std. Error t Value Pr(> | t | )
(intercept) -22.20 17.83 -1.24 0.22
imprinting 12.53 11.09 1.13 0.26
gender 17.19 10.86 1.58 0.12
age 1.24 0.43 2.87 0.00
imprinting:gender -5.85 6.62 -0.88 0.38
imprinting:age -0.41 0.27 -1.52 0.13
gender:age -0.54 0.27 -2.01 0.05
imprinting:gender:age 0.22 0.16 1.34 0.18
Table 14: Imprinting in CMT1A
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3.2 Evaluation of secondary clinical outcome measures 
3.2.1 Spearman's ρ correlation
All secondary clinical outcome measurements were correlated and graphically depicted in a
correlation  matrix  according  to  Spearman‘s  ρ [Figure  4].  As  the  dominant  and the  non-
dominant  side  of  the  same  examination  correlate  highly,  the  measurements  for  the  non-
dominant  limb were discarded from further analysis  by agreement.  This circumstance  fits
adequately  the  natural  phenotype  of  CMT1A,  since  it  is  known to  cause  a  symmetrical
phenotype. The correlation of Ulnar SNAP (median) does not show strong correlations to any
other parameter, while its motor counterpart (CMAP) does. 
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Figure 4: Correlation matrix, Spearman‘s ρ; 
positive correlations are shaded in blue, while negative correlations are shaded in red. 
  3 Results
The items sensory symptoms, motor symptoms arms/ legs, pin sensibility, vibration, strength
arms/  legs,  Ulnar  CMAP  and  Ulnar  SNAP  are  depicted  in  a  binned  (0-4)  form.  High
correlations between all  CITEC©-handheld dynamometry values of the upper limbs indicate
that not all of these measurements are needed to outline the fine motor skills/ strength of the
upper extremities. 
3.2.2 Initial filtering 
The visual analogue scale (VAS) for the perception of pain in everyday life does not show
strong  correlation  to  other  candidate  sub-scores  (maximum  correlation  coefficient  0.41).
Therefore, the VAS measurement was  discarded from the analysis. 
The measurement of the pinch grip was not executed in more than half of the patients, since
the Italian cohort was initially recruited in the setting of a therapeutic trial with ascorbic acid
with a slightly altered study protocol (Pareyson et al., 2011). 
The SF-36 was excluded as a secondary clinical outcome measure, due to its unspecificity
towards CMT1A and its too inconvenient interpretation to be considered a feasible clinical
score parameter.
3.2.3 Binning of data
In order to achieve comparability with the CMTNS (Version 1), putative secondary clinical
outcome  measurements  were  categorized  into five  subgroups  according  to  the  degree  of
disease affection (0,1,2,3,4) by binning with respect to the 5-quantiles. The quantiles for the
grip strength variables were computed separately according to the patients' sex [Table 15] to
account for gender-specific differences. 
There was no significant difference in the CITEC©-dynamometry foot strength variables (foot
dorsal and plantar dynamometry) to justify any gender stratification here. 
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Clinical Parameter 0 1 2 3 4
10m Walk Test [sec] x ≤ 6 6 < x ≤ 7 7 < x ≤ 8 8 < x ≤ 10 x > 10






275 > x ≥ 208
208 > x ≥ 154
208 > x ≥ 162
154 > x ≥ 126
162 > x ≥ 118
126 > x ≥ 92
x < 118
x < 92





188 > x ≥ 138
158 > x ≥ 120
138 > x ≥ 112
120 > x ≥ 92
112 > x ≥ 77
92 > x ≥ 68
x < 77
x < 68
Foot Dorsal [N] x ≥ 192 192 > x ≥ 122 122 > x ≥ 72 72 > x ≥ 30 x < 30
Foot Plantar [N] x ≥ 274 274 > x ≥ 188 188 > x ≥ 136 136 > x ≥ 80 x < 80
Table 15: Binning of data with respect to gender-specific differences
3.2.4 Unbiased approach 
In order to evaluate secondary clinical outcome measures in context of the Charcot-Marie-
Tooth Neuropathy Score,  the binned data of 479 patients is being divided into significant
amounts of clusters using a heat diagram and various validation methods (average proportion
of  non-overlap  (APN),  average  distance  between  means  (ADM),  average  distance  (AD),
figure of merit (FOM), Connectivity, Dunn, Silhouette). Ideal parameters of putative scoring
systems are intended to distinguish better between these aforementioned clusters.
Furthermore, the information gain of the  parameters of the classical CMTNS and the putative
secondary clinical outcome measures is shown by an Analysis of Variance (ANOVA). The
parameters  are  being  added  one  at  a  time  for  further  analysis,  in  order  to  explore  the
significance (p≤0.05) of the information gain in distinguishing between the various clusters. 
In a last step, different modified versions of the Charcot-Marie-Tooth Neuropathy Score are
being compared with regard to scope of distribution. 
Ideally, a new modified score can add valuable information, shown by better distinguishment
of natural clusters and also distributes more evenly and widely than an un-modified CMTNS.
 - 30 -
  3 Results
3.2.5 Hierarchical clustering
The heat map [Figure 5] depicts the binned data of primary (CMTNS) and secondary clinical
outcome measures in 479 patients suffering from CMT1A. The colour-coding represents the
degree of severity (0-4). While dark-blue shaded fields represent normal  performance (0),
lighter shades indicate impairment in performance of the respective clinical parameter (graded
1-4). A vertical  section of the heat map shows the performance of a random single study
participant. Horizontal sections feature the various score items. 
A hierarchical clustering was performed on all study participants and all available parameters,
followed   by  certain  validation  techniques  (average  proportion  of  non-overlap  (APN),
average distance  between means  (ADM),  average distance  (AD),  figure  of  merit  (FOM),
Connectivity,  Dunn,  Silhouette) (Brock  et  al.,  2011)  [Table  16].  The  results  of  these
validation methods indicate two clusters of patients as confirmed by rank aggregation (Pihur
et al., 2009).
The graphical depiction of the two clusters in comparison to the classical CMTNS as box-
plots [Figure 5], reveals that the two clusters represent a weakly and a severly affected cohort
of CMT1A patients. The density plots emphasize the limitations of the current CMTNS, since
it shows a significant overlap of the two clusters and therefore poor discrimination between
these clusters. This finding justifies the need for a modified scoring system.
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Figure 5: Hierarchical clustering
The hierarchical clustering of the 479 CMT1A patients results in 2 cohorts. They represent a mildly
and severely affected set of patients. The CMTNS (Version 1) is unable to distinguish well between
these  two  cohorts.  Future  outcome  measures  will  be  tested  for  their  discriminatory  power  to









Table 16: Validation methods for number of clusters
Due to various validations  methods and following rank aggregation,  the statistically  best
fitting model consists of 2 patient clusters. 
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3.2.6 Analysis of Variance (ANOVA)
An Analysis  of  Variance  (ANOVA)  is  conducted  on  the  scored  primary  and  secondary
clinical parameters of all CMT1A patients with the two main clusters as targets [Table 17].
The parameters are added one at a time starting with the primary parameters and followed by
the secondary ones (shaded blue). The analysis shows the significance of the information gain
in cluster differentiation.   
Parameter p-value
Strength of Legs < 0.001
Motor Symptoms Arms < 0.001
Sensory Symptoms < 0.001
Ulnar CMAP (Median) < 0.001
Pin Sensibility  0.005
Strength of Arms  0.041
Motor Symptoms Legs  0.130
Vibration  0.291
Ulnar SNAP (Median)  0.468
Foot Dorsal (dominant foot) < 0.001
Fist Grip (dominant hand) < 0.001
10m Walk Test  < 0.001
Foot Plantar (dominant foot)  0.005
Three Point Grip (dominant hand)  0.673
9 Peg Hole Test (dominant hand)  0.717
Table 17: Analysis of Variance (ANOVA)
By an Analysis of Variance the discriminatory power between the 2 clusters of all outcome
measures was tested. The primary outcome measures of the CMTNS (Version 1) were given
priority. Still, four secondary outcome measures provide additional significant information in
differentiation between the two clusters. 
The Analysis of Variance displays that five out of nine parameters of the original CMTNS,
namely Strength of Legs, Motor Symptom Arms, Sensory Symptoms, Ulnar CMAP (Median)
and  Pin Sensibility  actually  contribute  significantly -  in this  ranked order -  to distinguish
between the two aforementioned clusters. 
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Four out of six tested secondary clinical outcome measures contribute additional information
in  distinguishing  between  the  two  patient  clusters,  after  already  taking  into  account  the
information of the nine parameters of the classical CMTNS. 
3.3 Score Hypotheses
Several  score hypotheses  are postulated regarding the results  of the Analysis  of Variance
(ANOVA) [Table 17]. 
1. Score  hypothesis  1  (CMTNS_full)  includes  all  nine primary  and the whole set  of
secondary clinical outcome measurements (max. 60 points).
2. Score hypothesis 2 (CMTNS_signif) contains all primary outcome measurements of
the classical CMTNS and adds the significant  parameters of the secondary clinical
outcome measurements (max. 52 points).
3. Score hypothesis 3 (CMTNS_mod) restricts the score to parameters that significantly
add  information  in  distinguishing  between  the  two  clusters.  Therefore,  the  four
primary  and two secondary  clinical  outcome  measurements  that  do  not  show any
significant information gain are left out (max. 36 points). 
Figure 6: Score Hypotheses
The box plots show the different  score hypotheses in absolute values.  For better  comparison a
density plot with relative score values is shown. The CMTNS_mod provides the widest distribution
and reaches both extreme points (0 and 36 points in absolute score values).
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The graphical depiction of the absolute scores as box plots can only be utilized to compare the
width/ distribution of the classical CMTNS and the CMTNS_mod, since both are based on
nine score items (max. 36 points) [Figure 6].  In order to evaluate the distribution of the other
two score hypotheses in this context, density plots are being generated using relative scores.
The illustration displays that the classical CMTNS is focused on medium relative scores with
a narrow distribution. The CMTNS_signif and CMTNS_full show a wider distribution, while
the CMTNS_mod shows the widest distribution with least focus on medium relative scores.
Furthermore, the CMTNS_mod is the only score that stretches to both its extreme points (0
and 100%), which represents a valuable quality criteria in score generation.  Based on these
results  the  modified  score  represents  the  best  alternative  to  the  classical  CMTNS and  is
depicted below [Table 18].
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Parameter 0 1 2 3 4
strength of 
legs
normal 4+, 4, 4- on
foot
dorsiflexion 
</= 3 on foot
dorsiflexion 
</= 3 on foot
dorsiflexion
















































275 > x ≥ 208
208 > x ≥ 154
208 > x ≥ 162
154 > x ≥ 126
162 > x ≥ 118





x ≤ 6 6 < x ≤ 7 7 < x ≤ 8 8 < x ≤ 10 x > 10
foot plantar 
(D) [Newton]
x ≥ 274 274 > x ≥ 188 188 > x ≥ 136 136 > x ≥ 80 x < 80
foot dorsal 
(D) [Newton]
x ≥ 192 192 > x ≥ 122 122 > x ≥ 72 72 > x ≥ 30 x < 30
Ulnar CMAP 
(Median) 
 > 6 mV
(> 4 mV)
 4.0 - 5.9 mV
(2.8 - 3.9 mV)
 2.0 - 3.9 mV
(1.2 - 2.7 mV)
 0.1 - 1.9 mV
(0.1 - 1.1 mV)
 absent
(Absent)
Table 18: Modified CMTNS (CMTNS_mod)
The modified CMTNS consists only of significant parameters of the CMTNS (Version 1) and
selected  secondary  clinical  outcome  measures.  Non-significant  parameters  were  omitted.
Direct  comparibility  to  the  CMTNS (Version  1)  is  possible,  due  to  the  same  amount  of
parameters and score levels (0-36).
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4 Discussion
4.1 Study participants
The present analysis focuses on patients suffering from Charcot-Marie-Tooth disease type 1A
in Western Europe.  A total  of 479 CMT1A patients were clinically examined within five
European  clinical  centres  (Italy,  Spain,  Czech  Republic  and Germany)  and in  context  of
baseline assessments of the ascorbic acid trial in Italy and the United Kingdom (Pareyson et
al.,  2011).  The participants can be considered a representative cohort  of CMT1A patients
compared to the general population, since age, BMI and gender ratio reflect average values
[Table  11].  The  fact  that  the  average  CMTNS  displays  medium  affection,  needs  to  be
interpreted carefully, since the CMTNS in general tends to vary little [Figure 5].  Taking into
account the slow progression of the disease, its non-lethal nature, strikingly varying degrees
of disease affection and the limited number of specialised study centres per country, CMT1A
patients  are  possibly only willing  to  participate  in  non-therapeutic  trials  like  these,  if  the
psychological  strain exceeds the effort  of travelling  to a  remote  location to  be examined.
Therefore,  the allegedly averagely-affected cohort, is possibly more severely affected than
expected.  Apart from that, the cohort cannot be examined in terms of associated diseases/
complications.  Even though minor side diagnoses and medications were noted,  severe co-
morbidities constituted exclusion criteria to the prospective clinical trial to avoid confounding
factors. Nevertheless, the number of participants appears sufficient for score generation and
represents one of the largest CMT1A cohorts ever examined. 
4.2 Secondary clinical outcome measurements
Selected secondary clinical outcome measures are proven to be valid and to possess excellent
inter- and intrarater reliability (Solari et al., 2008). These tools are easy to perform and do not
need  any  invasive  or  potentially  harmful  diagnostic  examinations.  The  use  of  secondary
clinical outcome measures still needs to be restricted, in order to avoid redundancy, to test
only  characteristic  features  of  the  disease  of  interest  and  to  retain  the  feasibility  in  an
everyday clinical setting. Moreover, the quality of secondary outcome measures varies and
some outcome measures, e.g. the dynamometry of the lower extremities, are controversial,
since the examiner needs to fixate the patient's leg. Even though, the dynamometry usage in
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CMT patients shows low measurement errors and an excellent retest-reliability (Burns et al.,
2005), I highly recommend the usage of a leg fixation device (Solari et al., 2008) to avoid
inaccuracies. Furthermore, secondary clinical outcome measures test only the consecutive loss
of function and do not give insights into the affection of the nerve itself,  as e.g.  electro-
physiology and magnetic resonance imaging studies do. 
4.3 Score generation
4.3.1 Approach
The statistical approach included initial filtering, Spearman’s ρ, binning of data with respect
to gender specific differences, hierarchical clustering and an Analysis of Variance (ANOVA)
followed by comparison of different score hypotheses. 
Statistically, the comparison of every outcome measurement with its conformity towards the
CMTNS is inaccurate, since according to this approach one would assume the CMTNS to
represent the 'gold standard' and any further improvement of a modified score can - in its best
case  scenario  -  merely  reflect  the  classical  CMTNS.  Therefore,  in  an  unbiased  approach
towards  score  generation,  the  standard  of  reference  is  for  instance  the  evidence-based
existence of two patient clusters after various examinations. These clusters represent in this
case a mildly and a severely affected group of patients. Testing the discrimination power of
the  classical  CMTNS  in  context  of  these  two  clusters,  is  supposed  to  analyse  its  own
accuracy.  The disability  of  the  classical  CMTNS to distinguish  between the  two clusters
without a significant overlap [Figure 5], reveals its imprecision and justifies a modification,
while  still  acknowledging its  power to differentiate  between extremes of mild  and severe
affection. An Analysis of Variance (ANOVA) [Table 17] starting with the primary outcome
measures of the CMTNS and followed in the ranked order of secondary clinical  outcome
measurements,  reflects  the  information  gain  in  discriminating  between these  two referred
clusters. Furthermore, it reveals unnecessary secondary clinical outcome measures as well as
the redundant primary score parameters, with their information already being incorporated by
other parameters of the CMTNS (Version 1). 
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4.3.2 Score comparison
In a clinical setting, the framework of a scoring system contains the advantage of being end-
user friendly and self-explanatory.  The results are given in absolute  integral  numbers and
allow direct comparison irrespective of e.g. age-specific effects. In order to implement the
mentioned results of significant clinical outcome measures in a new/ modified scoring system,
various hypotheses were formed. In anticipation of a wider distribution outreaching to its both
extreme endpoints, the various score hypotheses (full, sign., mod.) and the classical CMTNS
are  graphically  depicted  in  form  of  box  and  density  plots  [Figure  6].  The  best  overall
performance  is  achieved  in  the  mod_CMTNS  by  not  only  adding  significant  secondary
clinical  outcome measures,  but  also  by removing  redundant  primary  score parameters.  A
length-dependent analysis will evaluate the important aspect of 'change over time', which is
being examined at the moment. The preliminary results of 10 patients show that all patients'
symptoms  deteriorated.  While  the  CMTNS  (Version  1)  increased  about  1.2  points,  the
modified CMTNS value increased to 2.9 points. While, these data give promising insights to
the  'change over  time'  of  the  modified  CMTNS,  only  a  more  powerful  length-dependent
analysis will justify the replacement of any other scoring system. Furthermore, the secondary
clinical outcome measures are proven to be inter- and intrarater reliable (Solari et al., 2008),
but the modified CMTNS as a whole also needs to be tested for these quality criteria. 
4.4 Clinical relevance
The  modified  Charcot-Marie-Tooth  Neuropathy  score  (mod_CMTNS)  is  of  distinctive
clinical relevance, since it represents an appropriate clinical outcome measurement to asses
the disease severity of Charcot-Marie-Tooth patients with focus on subtype 1A. Furthermore,
the mod_CMTNS is relatively easy to  perform and does not  require  any further  invasive
diagnostic tools. This evidence-based scoring system is supposed to provide the necessary
setting  for  future  therapeutic  trials.  Since  the  classical  CMTNS  depicts  the  disease
progression merely in a range between 0.2. and 0.686 points/ year (Shy et al., 2008; Pareyson
et al.,  2011), clinical  trials  can not be realized within a reasonable amount of time at the
moment.
Moreover, the classical CMTNS declares the majority of patients as averagely affected and is
not  able  to  distinguish  well  between  the  two  aforementioned  patient  clusters.  Thus,  an
alteration of the existing score in addition to the establishment of biomarkers is needed, in
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order to avoid systematic trial errors. A first approach was the testing of biomarkers of the
CMT rodent model in a subset of 46 CMT1A patients. A correlation between the CMTNS and
two genes of interest in human skin biopsies could be detected (Fledrich et al., 2012). This
approach will be expanded to a bigger cohort and compared with the modified CMTNS. 
4.5 Perspective
The perspective of this clinical trial includes the examination of length-dependent alterations
in  the  modified  CMTNS  (mod_CMTNS).  For  this  reason,  CMT1A  patients  will  be  re-
examined exactly three years after their initial study participation. Aim of this investigation is
to test, whether the alterations over time in the mod_CMTNS exceed the ones of the classical
CMTNS per year (Shy et al., 2008; Pareyson et al., 2011). Preliminary findings in the first 10
study participants have to be confirmed in a larger cohort. In that respect the mod_CMTNS,
which was specifically designed for subtype 1A, will also be tested for other subtypes of
CMT in order to evaluate its respective validity and reliability on a larger scope.
Furthermore, the new modified CMTNS (mod_CMTNS) will be used to re-evaluate all study
participants  according to their  degree of disease affection.  This data set  will  be linked to
individual gene expression levels in skin biopsies and whole blood samples. Sample candidate
genes have been already identified in a transgenic rodent model and translated into a small
cohort of CMT1A patients (Sereda et al., 1996; Fledrich et al., 2012). The larger cohort is
anticipated to enable the final validation of biomarkers in respect to disease severity. These
biomarkers in addition to the new clinical scoring system are needed to start therapeutic trials
with CMT1A patients. So far, appropriate outcome measurements for the therapeutic effect of
drugs in CMT1A patients do not exist. It is planned to pursue an investigator-driven trial with
either  a progesterone antagonists  or curcumin supplements  in the long run (Sereda et  al.,
2003; Meyer zu Hörste et al., 2007; Carter et al., 2008). 
Furthermore,  the  cumbersome  patient  recruitment  of  the  past  is  being  optimized  at  the
moment by establishing a Europe-wide online patient registry (CMT-NET). 
Apart from pharmacological ways of intervention, physical therapy is currently still the best
symptom  alleviating  treatment  for  CMT1A  patients.  It  is  even  recommended  that  CMT
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patients  undergo rehabilitation  treatment  twice per  year  (Maggi  et  al.,  2011).  Recently,  a
collaboration was initiated with the Neurology Department of the rehabilitation clinic in Bad
Karlshafen/ Germany and the Max-Planck Institute for Experimental Medicine in Göttingen/
Germany.  Its  aim is  to  offer  the  study participants  from Germany a new evidence-based
approach on rehabilitation with special focus on proprioception, stretching, fine motor skills
and CMT1A-specific exercises. The outcome of this treatment will again be measured with
the help of primary and secondary clinical outcome measurements (including the modified
CMTNS).
Finally,  the  skin  biopsies  in  4%  PFA  will  be  subject  to  various  histological/
immunohistological  investigations.  Special  interest  lies  in  the  quantification  of  Meissner
corpuscles as a histological outcome measure in CMT1A (Saporta et al., 2009). Preliminary
trials with hematoxylin and eosin staining  [Figure 7] and immunohistochemistry trials with
PGP9.5 antibodies have been performed.  
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Figure  7:  hematoxylin  and  eosin  staining  of  a  human  skin
biopsy
The sample  skin  biopsy  was  performed  with  a  3  mm biopsy
punch device in  the medial  index finger of the non-dominant
hand of a healthy control. 
  5 Summary
5 Summary
This dissertation is based on a clinical prospective study and represents the data of a multi-
centre, prospective European clinical trial on the hereditary peripheral neuropathy Charcot-
Marie-Tooth disease subtype 1A (CMT1A)/ (HMSN1A). Additional patients were included
through the baseline assessment of the ascorbic acid trial in Italy and the United Kingdom
(Pareyson et al., 2011).
The  objective  of  the  biomarker  trial  is  to  validate  new  secondary  clinical  outcome
measurements and to generate biomarkers in skin biopsies as well as in whole blood. While
the analysis of biomarkers via gene chip analysis is in progress, the validation of secondary
clinical  outcome measures  has  led  to  a  critical  analysis  of  clinical  scoring systems,  with
special regard to the most commonly used Charcot-Marie-Tooth Neuropathy Score (CMTNS
Version 1) (Shy et al., 2005). 
In course of analysing the accuracy of primary and secondary outcome measurements, one of
the largest cohorts of patients with proven CMT1A was recruited. 479 patients from Italy, the
United Kingdom, Spain, Czech Republic and Germany were examined. Secondary clinical
outcome measurements, including the 9-hole-peg test, 10m-timed walking, VAS, SF-36, as
well as extensive dynamometry tests (pinch grip, three-point-grip, fist-grip, foot plantar and
dorsal flexion) were evaluated. 
Based on these results, different score hypotheses were tested to facilitate future therapeutic
trials in CMT1A patients and to establish an improved clinical assessment of disease severity.
This assessment will further allow a more accurate correlation between the clinical phenotype
of patients and their respective gene expression for the establishment of biomarkers.  A new
evidence-based clinical  scoring system (modified  CMTNS) with significantly contributing
secondary  clinical  outcome  measures  was  designed.  The  modified  CMTNS consists  of  9
parameters, which add significant information to differentiate between two new found clusters
of patients. These clusters divide the cohort into mildly and severely affected patient groups.
The established Charcot-Marie-Tooth Neuropathy Score (Version 1) is unable to differentiate
clearly between these two groups of patients. Furthermore, certain parameters of the existing
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score (strength of arms, motor symptoms legs, vibration and Ulnar SNAP) were found to be
redundant and therefore omitted in the modified version of the score. The left out parameters
were replaced with significant secondary clinical outcome measures (foot dorsal, foot plantar,
fist grip and 10m walk test), which are proven to be reliable and valid (Solari et al., 2008). A
length-dependent  analysis  is  still  necessary to  detect  the  change over  time in  this  slowly
progressive neuropathy. A preliminary analysis of patients, who were recruited at a second
time point approximately three years  after  the initial  assessment,  shows that the modified
CMTNS depicts the deterioration of the disease better than the CMTNS (Version 1). 
The modified CMTNS will help to establish biomarkers, it will facilitate the more accurate
assessment of disease severity and therefore lay the foundation of future therapeutic trials in
patients suffering from CMT.
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6 Appendix
6.1 Case Report Form 
Case Report Form
study:
Validation of prognostic and diagnostic markers in CMT1A disease (HMSN1A)
Date of consent      
Date of participation      
Patient data:
Initials:       Patient number:      
birthdate:       sex:  female      male
age:       weight:       Kg
diagnosis:       height:       cm
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Name of examiner (Physician):                               
Name of clinic:                                    
Informed consent available:
(see attached)
 yes  no
Head of the study: name, address, telephone, email 




Clinical manifestation since:      
Proof of disease since:      





Informed consent  yes  no
Genitial evidence of subtype 1A  yes  no
Clinical manifestation of CMT1A  yes  no
Patient > 18 years and < 70 years  yes  no
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Exclusion Criteria
Other neurological or psychiatric disorders  yes  no
Drug-, medication- and/or alcohol abuse  yes  no
Other symptoms  yes  no
Lack of cooperation  yes  no
CMTNS:     (Shy et al., 2005)             






 right   left







dominant side  right   left
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10m-walking test: 
1 1. trial:                                 time (in sec.):        ___________
2 2. trial:                                 time (in sec.):        ___________
3 3. trial:                                 time (in sec.):        ___________
_____________________________________________________________
 mean:                                   time (in sec.):        ___________
9-peg-hole-test:
1.: non-dominant hand:                                   
 1. trial:                                 time (in sec.):        ___________
 2. trial:                                 time (in sec.):        ___________
       
 mean:                                  time (in sec.):        ___________
                                                                  - 49 -
  
2.: dominant hand: 
 1. trial:                                 time (in sec.):        ___________
 2. trial:                                 time (in sec.):        ___________
       
 Mean:                                  time (in sec.):        ___________
3mm skin biopsy:
 location:               _________________________
 code of biopsy:                  CMT1A – I_I_I_I – I_I_I_I
Documentation of unexpected incidents:
                                                                  - 50 -
  
Documentation of change in protocol:
Other:
1 SF-36 filled-in:                               yes □                      no □    
                                       
2 VAS marked:                                 yes □                      no □ 
 VAS-value:                           I_I_I_I mm
date:   I_I_I.I_I_I.I_I_I              examining physician:
                                                         name:   ____________________
                                                        
                                                 signature:     ____________________
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